Search results for: Multi-Indication Medicines
Filter search results
Performance-Based Risk Sharing in Health Care: Current Status
17 April 2013
Performance-based risk sharing arrangements for prescription medicines and other treatments are attractive to payers because they promise to base what is paid for a treatment on whether/how well it actually…
Recently Published: Reports on Policy Options for Formulary Development in Middle-income Countries and A Case Study from Mexico
4 January 2017
…and recommend methods that could help MICs efficiently and effectively identify medicines for formulary inclusion. The first report presents a framework for developing medicines formularies which combines macro-level decision making…
Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market
12 December 2017
…Health Select Committee on ‘Brexit: the regulation of medicines, medical devices and substances of human origin’. Giving evidence to the committee today, Steve Bates, CEO of the BIA, will…
Moving the Needle on Value – OHE Launches Research on US Value-Based Healthcare
10 June 2019
…been applied almost exclusively to medicines and medical technology. Similarly, there has been significant political and media attention given to the cost of medicines. But, this attention in terms of…
What is the Role of HTA for Biosimilars?
1 April 2014
…ten experts: leading academics and representatives from the UK medicines regulatory agency, the three… This Briefing summarises the results of a roundtable convened by OHE to discuss using HTA to…
Pharmacist in Society
7 January 1964
…recommended and prescribed medicines. Despite protests from the physicians, the apothecaries ‘legal right to give medical advice was upheld in a House of Lords’ judgement in 1703 and, under the…
Understanding Social Preferences Regarding the Prioritisation of Treatments Addressing Unmet Need and Severity
1 December 2012
The UK Government is proposing to include “burden of illness” criteria in its scheme for value based pricing of branded medicines, potentially according higher rewards to medicines that treat more…
Measuring Health: a Practical Approach
7 January 1988
In Britain, the tax-payer pays the lion’s share of the national bill for medicines through the tax-supported NHS. There can be no doubt that the supplier of this long list…
Trade and Price Differentials for Pharmaceuticals: Policy Options
1 May 1997
…as Spain and, in the future, the countries of Eastern Europe. In addition, since 1995 new medicines that are approved by the European Medicines Agency are automatically approved in all…